Login to Your Account

Adolor Suffers Setback On FDA Request For More Entereg Data

By Aaron Lorenzo

Tuesday, November 7, 2006
The FDA delayed approving Adolor Corp.'s Entereg (alvimopan) for postoperative ileus yet again, pending additional safety data, causing the company's shares to tumble by 44.8 percent on Monday. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription